NEW HAVEN, Conn., July 11, 2019 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN), has launched a
campaign called 'Demand More' highlighting what patients want and
need from an acute treatment of migraine in their own words.
Patients define real relief from migraine as fast and reliable pain
relief, with the ability to return to function quickly and a
sustained effect without the need for repeat dosing. Patients want
more from their acute treatment, desiring new options with fewer
side effects. The company introduced the campaign to healthcare
providers at the 61st Annual Scientific Meeting of the
American Headache Society (AHS), July
11-14, 2019.
The 'Demand More' campaign is based on research that suggests
patients aren't getting the relief they want and need from their
current acute treatments. In surveys of patients with migraine, 56
percent of patients reported they still experienced migraine pain
two hours post-treatment,1 and 54 percent of patients
taking existing acute treatments reported inadequate pain relief at
24 hours.1 Approximately 48 percent of patients weren't
satisfied with their ability to function after taking their current
acute treatment.2 Approximately 67 percent of patients
reported they delayed or avoided acute medications due to concerns
about side effects.3
"Patients want more from acute treatment of migraine, and there
is a growing demand and market for new options," said BJ Jones,
Chief Commercial Officer, Migraine and Common Diseases, Biohaven.
"We are committed to increasing awareness among physicians about
how patients define real relief and what patients want and need
from their acute treatment of migraine."
According to the American Headache Society's (AHS) 2018
Consensus Statement, acute treatments should give patients fast,
consistent relief of migraine symptoms, without
recurrence.4 Additionally, data shows that inadequate
acute treatment is associated with an increased risk for increasing
migraine frequency and severity (disease progression to Chronic
Migraine5).
The campaign engages healthcare providers via a unique exhibit
experience, microsite, digital media, and interactive components
that allow them to add their voice to the movement and to highlight
what they want most for their patients from an acute treatment for
migraine. It will roll out to patient audiences in the near future.
To learn more about the campaign, visit the Biohaven Booth #315 at
the AHS meeting or www.realrelieffrommigraine.com.
About Migraine
Migraine is a debilitating and recurrent disease
characterized by attacks lasting four to 72 hours with multiple
symptoms, including pulsating headaches of moderate to severe pain
intensity that can be associated with nausea or vomiting, and/or
sensitivity to sound (phonophobia) and sensitivity to light
(photophobia). There are over 39 million people in the U.S. who
suffer from migraine and the World Health Organization classifies
migraine as one of the 10 most disabling medical illnesses. There
is a significant unmet need for new acute treatments for migraine
as there has been only modest improvement in acute treatment since
the 1990s.
About Biohaven
Biohaven is a clinical-stage biopharmaceutical company with a
portfolio of innovative, late-stage product candidates targeting
neurological diseases, including rare disorders. Biohaven has
combined internal development and research with intellectual
property licensed from companies and institutions including
Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and
Massachusetts General Hospital. Currently, Biohaven's lead
development programs include multiple compounds across its CGRP
receptor antagonist, glutamate modulation and myeloperoxidase
inhibition platforms. More information about Biohaven is available
at www.biohavenpharma.com.
Forward-Looking Statements
This news release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements involve substantial risks and
uncertainties, including statements that are based on the current
expectations and assumptions of the Company's management. All
statements, other than statements of historical facts, included in
this press release regarding the Company's business and product
candidate plans and objectives are forward-looking statements.
Forward-looking statements include those related to: the
effectiveness and safety of rimegepant, the expected timing,
commencement and outcomes of the Company's planned and ongoing
clinical trials, the timing of planned interactions and filings
with the FDA, the timing and outcome of expected regulatory
filings, the potential commercialization of the Company's product
candidates and the potential for the Company's product candidates
to be first in class or best in class therapies. The use of certain
words, including "believe", "continue", "may", "on track",
"expects" and "will" and similar expressions, are intended to
identify forward-looking statements. Various important factors
could cause actual results or events to differ materially from
those that may be expressed or implied by our forward-looking
statements. Additional important factors to be considered in
connection with forward-looking statements are described in the
"Risk Factors" section of the Company's Annual Report on Form 10-K
filed with the Securities and Exchange Commission on February 28, 2019 and the Company's Quarterly
Report on Form 10-Q for the quarter ended March 31, 2019, filed with the Securities and
Exchange Commission on May 8, 2019.
The forward-looking statements are made as of this date and the
Company does not undertake any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
Biohaven Contact
Dr. Vlad
Coric
Chief Executive Officer
Vlad.Coric@biohavenpharma.com
Media Contact
Mike
Beyer
Sam Brown Inc.
(312) 961-2502
mikebeyer@sambrown.com
References:
- Lipton R, Munjal S, Buse D, et al. Predicting Inadequate
Response to Acute Migraine Medication: Results From the American
Migraine Prevalence and Prevention (AMPP) Study. Headache.
2016;56(10):1635-1648.
- Bigal M, Rapoport A, Aurora S, et al. Satisfaction With Current
Migraine Therapy: Experience From 3 Centers in the US and
Sweden. Headache.
2007;47(4):475-479.
- Gallagher R, Kunkel R. Migraine Medication Attributes Important
for Patient Compliance: Concerns About Side Effects May Delay
Treatment. Headache. 2003;43(1):36-43.
- American Headache Society. The American Headache Society
position statement on integrating new migraine treatments into
clinical practice [published online December
10,
2018]. Headache. doi: 10.1111/head.13456.
- Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute
treatment of episodic migraine is associated with new-onset chronic
migraine. Neurology. 2015;84(7):688-695.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohaven-launches-demand-more-campaign-at-2019-american-headache-society-annual-scientific-meeting-highlighting-patient-needs-in-acute-treatment-of-migraine-300883139.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.